INTRODUCTION

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

A cascade of protein kinases is a commonly used mechanism for amplifying and disseminating signals that control metabolism, growth, survival, and differentiation in eukaryotic cells. In animal cells, recruitment of phosphatidylinositol 3-kinase by growth factor receptors generates 3-phosphoinositides, which stimulate 3-phosphoinositide-dependent protein kinase-1 (PDK1) (for review, see Toker and Newton, 2000; Vanhaesebroeck and Alessi, 2000). Activated PDK1 phosphorylates and activates multiple downstream targets, including protein kinase B/c-Akt (Brazil and Hemmings, 2001; Lawlor and Alessi, 2001), p70 S6 kinase (Alessi et al., 1998; Kozma and Thomas, 2002), protein kinase C (PKC) isoforms (Chou et al., 1998; Le Good et al., 1998), and serum- and glucocorticoid-inducible protein kinase (SGK) isoforms (Kobayashi and Cohen, 1999; Kobayashi et al., 1999), thereby eliciting physiological responses.

We have demonstrated previously that, in budding yeast (Saccharomyces cerevisiae), Pkh1 and Pkh2 are the homologs and functional equivalents of mammalian PDK1. Pkh1 and Pkh2 share an essential function because pkh1 and pkh2 single mutants are viable, whereas a pkh1 pkh2 double mutant is inviable. Expression of human PDK1 rescues the lethality of a pkh1 pkh2 strain (Casamayor et al., 1999). The PDK1 enzymes from Caenorhabditis elegans, Drosophila melanogaster, and Homo sapiens all possess a C-terminal pleckstrin homology (PH) domain that binds phosphatidylinositol (PtdIns)(3,4,5)P₃ and PtdIns(3,4)P₂ (Stephens et al., 1998; Currie et al., 1999; Fruman et al., 1999). However, S. cerevisiae does not produce PtdIns(3,4,5)P₃ or PtdIns(3,4)P₂ (Hawkins et al., 1993; De Camilli et al., 1996). Moreover, Pkh1 and Pkh2 lack discernible PH domains, and PDK1 lacking its PH domain was sufficient to rescue the growth of pkh1 pkh2 cells (Casamayor et al., 1999), suggesting that the activity of Pkh1 and Pkh2 in yeast does not depend on phosphoinositides. It was shown subsequently that sphingosine (4-dehydro-sphinganine) can also stimulate mammalian PDK1 autophosphorylation and increase its ability to phosphorylate in vitro known PDK1 substrates, such as c-Akt and PKC (King et al., 2000). Correspondingly, it has been reported recently that Pkh1 and Pkh2 can be activated in vitro by nanomolar concentrations of the major sphingoid base in yeast, phytosphingosine (4-hydroxy-sphinganine) (Friant et al., 2001). Moreover, endocytosis in yeast seems to require sphingoid base synthesis and overexpression of Pkh1 or Pkh2 can suppress this requirement (Friant et al., 2001), suggesting that sphingoid bases activate a signaling pathway involving Pkh1 and Pkh2.

Mammalian PDK1 activates its downstream targets by phosphorylating a Thr residue (starred) in a sequence motif, Thr*-Phe-Cys-Gly-Thr-X-Glu-Tyr (where X represents any amino acid), that lies within the "activation loop" of their catalytic domains (Hanks and Hunter, 1995) and is unique to and conserved in all known PDK1 substrates. Full activation of c-Akt/PKB and other PDK1 targets also seems to require phosphorylation at a second site (starred) situated in a hydrophobic motif, Phe-X-X-Ar-Ser*/Thr*-Ar (where Ar represents an aromatic residue), that is located near the C terminus of each of these enzymes (Toker and Newton, 2000; Vanhaesebroeck and Alessi, 2000). In S. cerevisiae, four previously characterized protein kinases possess both of these motifs, suggesting that they are physiological substrates of Pkh1 and/or Pkh2. These four protein kinases are the products of the following genes: YPK1 (Maurer, 1988), YKR2/YPK2 (Maurer, 1988; Chen et al., 1993), PKC1 (Levin et al., 1990), and SCH9 (Toda et al., 1988). Studies from this laboratory have demonstrated that Ypk1 is a direct substrate of Pkh1 (Casamayor et al., 1999) and that Ykr2 is phosphorylated by Pkh2 (Torrance, 2000). Similarly, it has been shown that Pkc1 can also be phosphorylated by Pkh1 and Pkh2 (Inagaki et al., 1999; Friant et al., 2001). Reduced Pkc1 activity was observed in a pkh1-1^ts pkh2 strain, and the temperature sensitivity of this strain was partially suppressed by a dominant PKC1(R398P) allele, suggesting that Pkh1 and Pkh2 are required for Pkc1 function in vivo (Inagaki et al., 1999).

The catalytic domains of Ypk1 and Ykr2 are 88% identical and these proteins also share extensive homology across their N- and C-terminal extensions. Moreover, the catalytic domains of Ypk1 and Ykr2 closely resemble (55% identity) that of mammalian SGK. Indeed, cells lacking Ypk1 or Ykr2 are viable, whereas cells lacking both Ypk1 and Ykr2 are inviable (Chen et al., 1993; Schnieders, 1996), and expression of mammalian SGK rescues this inviability (Casamayor et al., 1999). Furthermore, both purified PDK1 and purified Pkh1 phosphorylate the same residue (Thr504) in the consensus motif in purified Ypk1, and Ypk1 phosphorylation is significantly diminished in vivo in cells lacking Pkh1 (Casamayor et al., 1999). Thus, just as SGK is a downstream target of PDK1 in animal cells, Ypk1 and Ykr2 seem to act downstream of Pkh1 and Pkh2 in yeast. Moreover, lipid-derived signals are required as upstream activators in both pathways, 3-phosphoinositides and sphingosine in the case of PDK1 and closely related sphingoid bases in the case of Pkh1 and Pkh2. Consistent with this view, overexpression of Ypk1 confers resistance to myriocin (ISP-1), an antibiotic that specifically inhibits serine C-palmitoyltransferase (product of the LCB1 gene), which is the enzyme responsible for sphinganine biosynthesis (Sun et al., 2000).

Herein, we describe experiments that address the genetic and biochemical interrelationships between Pkh1 and Pkh2 and Ypk1 and Ykr2, which we undertook to try to understand the reason for the redundancies within these protein kinase cascades. To provide further insight, we also investigated the subcellular localization of all four proteins. Finally, as two independent approaches for discerning the physiological function of the Ypk1 and Ykr2 enzymes, we selected for dosage suppressors and also for chromosomal mutations that suppress the lysis phenotype of ypk1-1^ts ykr2 cells.

	MATERIALS AND METHODS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

Strains and Growth Conditions

Yeast strains used in this study are listed in Table 1. Standard rich (YP) and defined minimal (SC) media (Sherman et al., 1986), containing either 2% glucose (Glc), 2% raffinose (Raf), or 2% galactose (Gal) as the carbon source and supplemented with appropriate nutrients to maintain selection for plasmids, were used for yeast cultivation. For gene expression from the galactose-inducible GAL1 promoter in liquid media, cells were pregrown to mid-exponential phase in SC containing 2% raffinose-0.2% sucrose (Raf/Suc) and then Gal was added to a final concentration of 2% and incubation continued for 2 h. In experiments involving growth on solid medium containing 5-fluoroorotic acid, 5-fluoroorotic acid was used at a concentration of 0.5 mg/ml (Boeke et al., 1984). Cells were grown routinely at 30°C, except for strains carrying temperature-sensitive mutations, which were propagated at their permissive temperature (26°C).

Recombinant DNA Methods

Escherichia coli strain DH5 (Hanahan, 1983) was used for the construction and propagation of plasmids. Conventional recombinant DNA methods were used for the construction of plasmids (Sambrook et al., 1989). The sequences of constructs that contained DNA fragments amplified by polymerase chain reaction (PCR) were verified by the dideoxy chain termination-sequencing method (Sanger et al., 1977). Native and Turbo Pfu polymerases (Stratagene, La Jolla, CA) were used for PCR, unless noted otherwise.

Plasmids

Plasmids pYPK1, pYKR2, pGAL-YPK1, pGAL-YKR2 (pAM1), pGAL-Ypk1-Myc (pAM54), pADH-YPK1, pRS316-YKR2 (pAM12), pGAL-PKH1 (pAM73), and pGAL-PKH2 (pAM79) have been described previously (Maurer, 1988; Kubo et al., 1989; Casamayor et al., 1999). To create plasmid pADH-YKR2 (pAM4), which constitutively overexpresses YKR2 from the ADH1 promoter, a 2.4-kb XhoI (blunt)-SalI fragment containing the entire YKR2 gene was excised from pYKR2, gel purified, and inserted into vector pAD4 M (Martin et al., 1990) that had been linearized with SmaI/SalI. To generate a version of Ykr2 tagged at its C-terminal end with the c-Myc epitope (Evans et al., 1985), a PCR-based method for precise gene fusion (Yon and Fried, 1989) was performed using the YKR2 sequence cloned in pUC18 as one template (pYKR2), and as the other template, pOGFP (E. Swartzman, this laboratory), which contains a sequence encoding the 16-residue version of the c-Myc epitope followed by a (His)₆ tag cloned in pBluescript (Stratagene); with three appropriate synthetic oligonucleotide primers: T3 (Stratagene); 5'-GGA CAT ATT GCA CTG TGT G-3' (RMN5), corresponding to sequences in YKR2 overlapping a DraIII site near the C terminus; and a "joiner" primer, 5'-TTC AGA AAT CAA CTT TTG TTC ACT AAT GCT TCT CCC CTG-3' (RMC), corresponding to the 3' end of the YKR2 coding sequence and the first several residues of the c-Myc epitope. An ~1.6-kb DraIII/KpnI fragment of the resulting PCR product was used to replace the corresponding segment in pYKR2, yielding pYkr2-Myc (pAM24). An ~3-kb NcoI/HindIII fragment from pYkr2-Myc was gel purified and used to replace the corresponding ~2.2-kb NcoI/HindIII segment in pGAL-YKR2 to create a 2-µm DNA-containing, LEU2-marked plasmid, pGAL-Ykr2-Myc (pAM59), that overexpresses Ykr2-Myc upon galactose induction. To generate a catalytically inactive ("kinase-dead") version of Ypk1, a PCR-based method for site-directed mutagenesis was performed using pYPK1 as the template and three appropriate synthetic oligonucleotide primers: 5'-CTT GAA CAC AGT AAG TAA CGG-3' (PKC2), corresponding to the flanking genomic sequence commencing 68-base pairs downstream of the stop codon; 5'-CAC AAA AAG TAT ACG CCT TGG CGG CAA TCA G-3' (PKD), where the underlined nucleotide is a silent mutation to introduce a BglI site, and the bold nucleotides correspond to an introduced alanine codon (GCG) in place of the native lysine codon (AAG); and 5'-GTC CAT CGA TGA TTT CGA TC-3' (Pseq2), corresponding to the coding strand of YPK1 starting at nucleotide position 1024. The resulting ~1.1-kb PCR product was digested with ClaI and NcoI, and the resulting ~850-base pair fragment was used to replace the corresponding segment in pYPK1, yielding pYPK1(K376A-KD) (pAM46). Conversion of the Lys residue at the equivalent position in all other protein kinases examined to date eliminates their catalytic activity (Hanks and Hunter, 1995). To generate a catalytically inactive (kinase-dead) version of Ykr2, a similar PCR-based approach for site-directed mutagenesis was performed using pYKR2 as the template, and three appropriate synthetic oligonucleotide primers: 5'-AGT ATA GCC CTG CCC CAA C-3' (Rseq2), corresponding to the noncoding strand of YKR2 commencing at nucleotide position 1544; 5'-CCC AAA AGA TTT ACG CCT TGG CGG CTC TGA G-3' (RKD), where the underlined nucleotide is a silent mutation to introduce a BglI site, and the bold nucleotides correspond to an introduced alanine codon (GCG) in place of the native lysine codon (AAG); and 5'-CGT GGG GTA ATG GCC TG-3' (Rseq3), corresponding to the coding strand of YKR2 starting at nucleotide position 66. The resulting ~1.4-kb PCR product was digested with NcoI and DraIII and used to replace the corresponding segment in pYKR2, yielding pYKR2(K373A-KD) (pAM47). Plasmid pYPK1(K376A-KD) was digested with AlwnI, converted to flush ends by treatment with T4 polymerase (NEB) and all four dNTPs then digested with SalI. The resulting 3.3-kb YPK1(K376A-KD)-containing fragment was gel purified and ligated into YEp351GAL that had been linearized by digestion with XbaI, converted to flush ends by incubation with T4 polymerase and all four dNTPs, and then digested with SalI. The resulting plasmid, pGAL-YPK1(K376A-KD) (pAM48), expresses a catalytically inactive allele [Ypk1-(K376A-KD)] from a 2-µm DNA-containing, LEU2-marked plasmid under control of the GAL1 promoter. An ~1.2-kb NcoI/SalI fragment from pYpk1-Myc was gel purified and used to replace the corresponding NcoI/SalI segment in pGAL-YPK1(K376A-KD) to create pGAL-YPK1(K376A-KD)-Myc (pAM49). An ~2.4-kb XhoI-HindIII fragment containing the entire YKR2(K373A-KD) allele was excised from pYKR2(K373A-KD), gel purified, and inserted into YEp351GAL that had been linearized with SalI and HindIII, to create a 2-µm DNA-containing, LEU2-marked plasmid, pGAL-YKR2(K373A-KD) (pAM50), that overexpresses catalytically inactive Ykr2 upon galactose induction. Galactose-inducible expression vectors that are URA3 based were constructed as follows. An ~3.3-kb BamHI/HindIII fragment carrying YPK1 was excised from pGAL-YPK1, gel purified, and ligated into YEp352GAL (Benton et al., 1994), which had been linearized with BamHI/HindIII, yielding YEp352GAL-YPK1 (pAM75). An ~3.8-kb BamHI/HindIII fragment from pGAL-Ypk1-Myc was gel purified and ligated into YEp352GAL that had been linearized with BamHI/HindIII, yielding YEp352GAL-Ypk1-Myc (pAM76). An ~2.2-kb BamHI/HindIII fragment from p2GAL-YKR2 was gel purified and ligated into YEp352GAL, which had been linearized with BamHI/HindIII, yielding YEp352GAL-YKR2 (pAM77). An ~3.0-kb BamHI/HindIII fragment from p2GAL-Ykr2-Myc was gel purified and ligated into YEp352GAL, which had been linearized with BamHI/HindIII, yielding YEp352GAL-Ykr2-Myc (pAM78). To generate an amino-terminal truncation of Ypk1, the following two-step approach was taken. First, an ~1.1-kb fragment corresponding to the last 344 amino acids of Ypk1 was amplified by PCR from pYPK1 with the following oligonucleotides: 5'-GGC GGA TCC ATG TCC AGA AAT AAA CCT TTG TCC-3' (PCT), corresponding to sequences in the middle of the YPK1 coding sequence, just upstream of the beginning of the catalytic domain, where the underlined nucleotides correspond to an introduced BamHI restriction site, and the bold nucleotides represent an introduced start codon (ATG); and 5'-CTT GAA CAC AGT AAG TAA CGG-3' (PKC2), corresponding to the flanking genomic sequence commencing 68-base pairs downstream of the stop codon. The resulting PCR product was digested with BamHI and NcoI, gel purified, and used to replace an ~2.6-kb BamHI/NcoI fragment in pRS315-YPK1(B/H). The resulting CEN-containing, LEU2-marked plasmid encodes an amino-terminal truncation of Ypk1, which contains only the catalytic domain, but essentially no promoter sequence, and is called pRS315-YPK1-N (pAM55). An ~1.2-kb NcoI/SalI fragment from pRS315-Ypk1-myc was gel purified and used to replace the corresponding NcoI/SalI segment in pRS315-YPK1-N to create a CEN-containing, LEU2-marked plasmid, pRS315-Ypk1-N-myc (pAM56), that encodes a myc-tagged version of the Ypk1 catalytic domain. To insert a promoter, an ~2.3-kb BamHI/SalI fragment from pRS315-YPK1-N was gel purified and inserted into YEp351GAL that had been linearized with BamHI/SalI to create a 2-µm NA-containing, LEU2-marked plasmid, pGAL-YPK1-N (pAM99), that overexpresses the amino-terminal truncation of Ypk1 upon galactose induction. Likewise, an ~2.0-kb BamHI/SalI fragment from pRS315-Ypk1-N-Myc was gel purified and inserted into YEp351GAL that had been linearized with BamHI/SalI to create a 2-µm NA-containing, LEU2-marked plasmid, pGAL-Ypk1-N-Myc (pAM100), that overexpresses a myc-tagged version of the amino-terminal truncation of Ypk1 upon galactose induction. To move these truncated Ypk1 derivatives into URA3-marked plasmids, an ~2.3-kb BamHI/SalI fragment from pGAL-YPK1-N was gel purified and inserted into YEp352GAL that had been linearized with BamHI/SalI to create a 2-µm DNA-containing, URA3-marked plasmid, YEp352GAL-YPK1-N (pAM101), that overexpresses the amino-terminal truncation of Ypk1 upon galactose induction. Similarly, an ~2.0-kb BamHI/SalI fragment from pGAL-Ypk1-N-Myc was gel purified and inserted into YEp352GAL that had been linearized with BamHI/SalI to create a 2-µm DNA-containing, URA3-marked plasmid, YEp352GAL-Ypk1-N-myc (pAM102), that overexpresses a myc-tagged version of the amino-terminal truncation of Ypk1 upon galactose induction. To generate a catalytically inactive derivative of the Ypk1-N allele, a 2.3-kb ClaI/HindIII fragment from pGAL-YPK1-KD, encoding the carboxy terminus (containing the K376A kinase-dead mutation of Ypk1) was gel purified and used to replace the corresponding segment in YEp352GAL-Ypk1-N-Myc. The resulting plasmid, YEp352GAL-Ypk1-N-KD (pFR30), overexpresses a catalytically inactive derivative of the amino-terminal truncation of Ypk1 upon galactose induction.

Protein Localization by Using Chimeras Containing Green Fluorescent Protein (GFP)

To create vectors for galactose-inducible expression of YPK1, YKR2, and PKH2, each fused to the carboxy terminus of a protein comprising three tandem repeats of an enhanced (S65T V163A) mutant of GFP, the following approach was taken. Two primers, 5'-GCG AGC GGG ATC CAT G, the first 18 bases of the gene-3' (primer A), where underlined bases correspond to an introduced BamHI site and start codon in bold; and 5'-GGC ACG CGT CGA CTT A, the last 18 bases of the gene-3' (primer B), where underlined bases correspond to an introduced SalI site and stop codon in bold, were used to amplify the entire open reading frames of the corresponding genes from genomic DNA. The PCR products were digested with BamHI and SalI and ligated into vector pGS836 (YCpGAL-3GFP) (Maurer et al., 2001) that had been digested with BamHI and SalI, yielding plasmids pGAL-3GFP-YPK1 (pFR33), pGAL-3GFP-YKR2 (pER2), and pGAL-3GFP-PKH2 (pER3). To create pGAL-3GFP-PKH1 (pFR37), the same approach was used, but due to the presence of BamHI and SalI restriction sites in the gene, two PCR products were made, one with primer A and a primer corresponding to the sequence 3' to the ClaI site present in PKH1, and the other with a primer 3' of the ClaI site and primer B. A three-way ligation was then used to ligate the two PCR products digested with BamHI and ClaI, or ClaI and SalI, into pGS836 that had been digested with BamHI and SalI.

Cells expressing the GFP constructs were grown to mid-exponential phase at 30°C in SC-Leu containing Raf/Suc and then induced with 2% galactose for 3 h. Nuclear DNA was stained with 4,6-diamidino-2-phenylindole (DAPI) by adding the dye directly in the medium at a concentration of 1 µg/ml for the last hour of growth. Rhodamine-labeled phalloidin was purchased from Molecular Probes (Eugene, OR). Samples of each culture were viewed directly with a TE300 fluorescence microscope (Nikon, Melville, NY) equipped with a 100×/1.4 Plan-Apo objective and a 1.4 numerical aperture condenser. Digital images were acquired with a bottom-ported Orca 100 charge-coupled device camera (Hamamatsu, Bridgewater, NJ) and Phase 3 Imaging Systems software (Northern Exposure, Inc., Glen Mills, PA). The fraction of lysed cells in cultures was assessed by direct counting of at least 200 cells after staining with a vital dye (LIVE/DEAD Yeast Viability kit; catalog no. 7009; Molecular Probes).

Antibody Production

To express a glutathione S-transferase (GST)-Ypk1 fusion protein in E. coli, an ~370-base pair fragment corresponding to the first 114 amino acids of Ypk1 was amplified by PCR from pYPK1 by using the following oligonucleotides: 5'-GGG GGG GGA TCC ATG TAT TCT TGG AAG TCA AAG TTT-3', where the underlined nucleotides correspond to an introduced BamHI site, and the bold nucleotides correspond to the start codon; and 5'-GGG GGG AAT TCT CAG GTG GCA TCA TTG GGT GTC CC-3', where the underlined nucleotides correspond to an introduced EcoRI site, and the bold nucleotides correspond to the reverse complement of an introduced stop codon. This PCR fragment was then digested with BamHI and EcoRI, gel purified, and ligated into the pGEX2T vector (Pharmacia, Peapack, NJ), which had been linearized with BamHI and EcoRI to create plasmid pGEX-Ypk1 (pAM5). To express a GST-Ykr2 fusion protein in E. coli, an ~360-base pair fragment corresponding to the first 111 amino acids of Ykr2 was amplified by PCR from pYKR2 by using the following olignucleotides: 5'-GGG GGG GGA TCC ATG CAT TCC TGG CGA ATA TCC AAG-3', where the underlined nucleotides correspond to an introduced BamHI site, and the bold nucleotides correspond to the start codon; and 5'-GGG GGG AAT TCT CAA CTC GGT CCC TGC GTC TCA GT-3', where the underlined nucleotides correspond to an introduced EcoRI site, and the bold nucleotides correspond to the reverse complement of an introduced stop codon. This PCR fragment was then digested with BamHI and EcoRI, gel purified, and ligated into the pGEX2T vector, which had been linearized with BamHI and EcoRI to create plasmid pGEX-Ykr2 (pAM6).

To prepare antigen, expression of GST-Ypk1(1-114) and GST-Ykr2(1-111) fusions from plasmids, pGEX-Ypk1 and pGEX-Ykr2, respectively, were induced in a protease-deficient E. coli strain BL21 (DE3)[pLys] (Studier, 1991) by addition of isopropyl--D-thiogalacto-pyranoside to a final concentration of 0.2 mM followed by incubation with aeration for 2 h at 30°C. Cells were harvested, washed once with ice-cold wash buffer (50 mM Tris-HCl pH 8, 0.5 mM dithiothreitol [DTT], 100 mM KCl, 1 mM phenylmethylsulfonyl fluoride, 0.05% NP-40, 1 mM EGTA, and 1 mM EDTA), and resuspended in 1/20 volume of wash buffer containing 1 M NaCl. Cells were disrupted by digestion with lysozyme (final concentration, 2 mg/ml) followed by sonication. Insoluble material was removed by centrifugation at 12,000 × g, and the soluble GST-Ypk1(1-114) or GST-Ykr2(1-111) proteins were purified by adsorption to, and elution from, glutathione-agarose beads (Pharmacia), essentially as directed by the manufacturer, except that elution was performed in the presence of 1 M NaCl and 20 mM glutathione. The purified proteins were used as immunogens to raise polyclonal antisera in adult female New Zealand White rabbits following standard immunization protocols (Harlow and Lane, 1988). The resulting anti-Ypk1 antibodies (serum #1446) and anti-Ykr2 antibodies (serum #1732) are specific to Ypk1 and Ykr2 and do not display any cross-reaction against the incorrect antigen. Anti-GFP antibodies were the generous gift of Roger Tsien and Charles Zuker (Department of Cellular and Molecular Medicine, University of California, San Diego, CA).

Preparation of Cell Extracts and Immunoblot Analysis

Yeast cells were grown at 30°C to mid-exponential phase (A_{600 nm} = 0.5-1), either in SC medium supplemented in a manner appropriate for maintenance of plasmids or in rich medium (YPGlc). If cells required galactose induction for expression from the GAL1 promoter, galactose was added to a final concentration of 2% and the cultures were incubated at 30°C for an additional 2 h. Cells were harvested by brief centrifugation, washed twice by resuspension and resedimentation in ice-cold lysis buffer (50 mM Tris-HCl pH 7.5, 5 mM EDTA, 3 mM DTT and 1 mM phenylmethylsulfonyl fluoride), and resuspended in 200 µl of the same buffer. Prechilled glass beads (0.45-0.6 mm in diameter) were added to the meniscus of the cell suspension, and lysis was achieved by vigorous vortex mixing for six 1-min intervals, with intermittent cooling on ice. To remove the glass beads, the bottom of the Eppendorf tube was punctured with a syringe needle (<0.5 mm in diameter) and inserted into another tube; the lysate was collected into the fresh tube by brief centrifugation in a clinical centrifuge. The crude extract was subjected to centrifugation at 30,000 × g for 15 min to remove unbroken cells and large debris. The protein concentration of the crude extract was measured using a dye-binding method (Bradford, 1976) with a protein assay kit as instructed by the manufacturer (Bio-Rad, Hercules, CA), by using bovine serum albumin (New England Biolabs, Beverly, MA) as the standard.

For immunoblot analysis, samples (50 µg of total protein) were diluted into SDS-PAGE sample buffer (Laemmli, 1970), subjected to electrophoresis in an 8-12% gel, and then transferred to nitrocellulose (Towbin et al., 1979). To detect Ypk1, rabbit polyclonal anti-Ypk1 antiserum #1446 was used at a dilution of 1:3000. To detect Ykr2, rabbit polyclonal anti-Ykr2 antiserum #1732 was used at a dilution of 1:3000. To detect proteins using the anti-c-Myc monoclonal antibody (mAb) 9E10, ascites fluid containing this mAb was used at a dilution of 1:10,000 (Evans et al., 1985). Immobilized immune complexes were detected using a commercial chemiluminescence detection system (Renaissance; PerkinElmer Life Sciences, Boston, MA) and x-ray film (Biomax MR; Eastman Kodak, Rochester, NY).

Immunoprecipitations

Yeast cultures to be used for immunoprecipitation analysis were grown as described above, and then rinsed in ice-cold IP buffer (20 mM Tris-HCl pH 7.5, 125 mM potassium acetate, 0.5 mM EDTA, 0.5 mM EGTA, 1 mM DTT, 1 µg/ml leupeptin, 1 µg/ml pepstatin A, 0.1% Triton X-100, and 12.5% glycerol). Glass beads were added to the meniscus of the cell suspension, and lysis was achieved by vigorous vortex mixing for eight 30-s intervals with intermittent cooling on ice. The lysate was clarified by centrifugation at 14,000 × g at 4°C for 30 min. The clarified extract was assayed for protein concentration, and a sample (1 mg of total protein) was diluted to a final volume of 200 µl in IP buffer. An aliquot (20 µl) of protein G/protein A-agarose beads (30% slurry) (Oncogene Science, Cambridge, MA) and a sample of an appropriate control antibody, either 2 µl of preimmune rabbit serum or 1 µg of purified mouse anti-T-cell receptor antibody (gift of James Allison, Department of Molecular and Cell Biology, University of California, Berkeley, CA), were added. The samples were then incubated on a roller drum for 1 h at 4°C to adsorb proteins that bound nonspecifically to the solid support and to rabbit or mouse IgG (preclearing). The beads were removed by centrifugation for 10 min in a microfuge, and the supernatant fraction was transferred to a fresh tube containing another aliquot (15 µl) of protein G/protein A-agarose beads and either 2 µl of anti-Ypk1 (or anti-Ykr2) polyclonal antiserum or 1 µl of anti-c-Myc (mAb 9E10) ascites, and incubated on a roller drum for 1 to 3 h at 4°C. The beads were sedimented by brief centrifugation in a microfuge and washed three times (1 ml each) with ice-cold IP buffer and collected by centrifugation for 1 min in a microfuge on maximum speed. Bead-bound immune complexes were solubilized in SDS-PAGE sample buffer and immediately boiled for 5 min in a water bath and then clarified by brief centrifugation in a Microfuge before resolution by SDS-PAGE. The proteins of interest were visualized as described above.

Immune-Complex Protein Kinase Assays

Cells expressing either wild-type or kinase-dead Ypk1-myc (or Ykr2-myc) under control of the GAL1 promoter were grown in SC containing Raf/Suc to an A_{600 nm} = 0.6, induced by addition of galactose (2% final concentration), incubated with shaking at 30°C for 2 h, collected by centrifugation, washed with ice-cold 1× phosphate-buffered saline, resuspended in 0.2 ml of ice-cold IP buffer, and lysed as described above. The resulting lysates were clarified by centrifugation at 4°C for 30 min at 30,000 × g. Protein concentration in the resulting crude extracts was determined by the Bradford (1976) method. A volume of extract containing 1 mg of total protein was immunoprecipitated with mAb 9E10 as described above. The immunoprecipitates were washed once with ice-cold IP buffer, once with ice-cold IP buffer containing 0.5 M NaCl, and twice with ice-cold buffer A (50 mM Tris-HCl pH 7.5, 0.1 mM EGTA, and 0.1% [by vol] 2-mercaptoethanol). As part of the final wash, the slurry of beads was split into two equal portions. For immunoblot analysis, SDS-PAGE sample buffer (~15 µl) was added directly to one sample of each bead suspension. For protein kinase assays, the activity of the Ypk1-myc or Ykr2-myc immune complex was assayed by adding 30 µl of a mixture containing 1 µM microcystin-LR, 10 mM Mg-acetate, 100 µM [-³²P]ATP (200-400 cpm/pmol), and 100 µM Cross-tide (GRPRTSSFAEG) (Cross et al., 1995), which we have documented previously is an excellent peptide phospho-acceptor substrate for Ypk1 and Ykr2 (Casamayor et al., 1999; Torrance, 2000). After incubation for 15 min at 30°C, each reaction was terminated by spotting a portion (45 µl) of the reaction mixture onto small squares of phosphocellulose paper (P81; Whatman, Maidstone, United Kingdom), which were washed and analyzed as described in detail previously (Alessi et al., 1995). In some experiments, samples of the immunoprecipitates were resuspended in an appropriate buffer (20 mM Tris-HCl pH 8.8 and 10 mM MgCl₂) and treated with shrimp alkaline phosphatase (0.25 U; US Biochemical, Cleveland, OH) in either the absence or presence of a mixture of inhibitors of this phosphatase (25 µM Na-orthovanadate and 100 µM -glycerol-phosphate, adjusted to pH 8).

Bioassays for Drug Sensitivity

An agar diffusion (halo) assay (Reneke et al., 1988) was performed to test the relative sensitivity of various strains to rapamycin, valinomycin, hygromycin B, cycloheximide, and polyoxin D. Nascent lawns of the strains to be tested were prepared by mixing ~2 × 10⁶ cells from a saturated culture with 2 ml of molten (55°C) 1% agar. The cell-containing agar was rapidly mixed and immediately poured evenly onto plates containing an appropriate medium. Various concentrations of rapamycin (50 and 500 ng/µl), hygromycin B (5 and 50 µg/µl), or the other drugs indicated, were spotted in the same volume (10 µl) onto sterile cellulose filter discs (0.6 cm), which were placed on the nascent lawn. The plates were incubated at 30°C, and photographed after 2 d.

Selection and Analysis of Dosage Suppressors

A library of restriction fragments of yeast genomic DNA cloned into a URA3-marked, 2-µm DNA-based vector, YEp352 (Hill et al., 1986), was introduced into strain YPT40 (ypk1-1^ts ykr2) (Casamayor et al., 1999) by selecting transformants on SCGlc-Ura medium at 26°C. Temperature-resistant clones were then selected by their ability to grow at 35°C. One suppressor plasmid obtained carried the EXG1 locus as the sole open reading frame. To create a plasmid that expressed EXG1 from a high-level constitutive promoter, two primers, 5'-GCG TCT CGA GAT GCT TTC GCT TAA AA-3', where the underlined bases correspond to an introduced XhoI site, and the start codon is in bold; and 5'-CGC CGG AGC TC T TAG TTA GAA ATT GTG CC-3', where the underlined bases correspond to an introduced SacI site, and the stop codon is in bold, were used to amplify the entire open reading frame of EXG1 from the library plasmid that was originally isolated as a dosage suppressor of the ypk1-1^ts ykr2 strain (see RESULTS). This 1.4-kb PCR product was digested with XhoI and SacI and ligated into vector pAD4 M that had been digested with SalI and SacI, yielding pADH-EXG1 (pAM88). To express PKC1 from its own promoter on a high copy number (2-µm DNA) plasmid, a 4.2-kb NsiI fragment containing the entire open reading frame of PKC1 as well as 560 base pairs upstream of the ATG and 175 base pairs downstream of the stop codon, was cut out of a genomic clone obtained by F. Owen Fields (this laboratory; Fields, 1991; Fields and Thorner, 1991) and ligated into the URA3-based plasmid YEp352 that had been linearized with PstI, yielding plasmid pPKC-PN, or into the LEU2-based plasmid YEp351 that had been linearized with PstI, yielding plasmid pFR32. To express BCK1-20 in a LEU2-based plasmid, the PvuI-PvuI fragment of plasmid pRS314-BCK1-20 (Lee and Levin, 1992) was replaced by the equivalent LEU2-containing fragment of plasmid pRS315, yielding plasmid pRS315-BCK1-20.

Selection and Analysis of Chromosomal Suppressor Mutations

A genomic DNA library containing Tn3::LacZ::LEU2 insertions (generous gift of Michael Snyder, Department of Biology, Yale University) was introduced into strain YPT40 (ypk1-1^ts ykr2) (Casamayor et al., 1999) by selecting transformants on SCGlc-Leu medium at 26°C. Temperature-resistant clones were then selected by their ability to grow at 35°C. Plasmids carrying genomic DNA corresponding to the sites of insertion were recovered as described in detail previously (Ross-Macdonald et al., 1999) and characterized by direct nucleotide sequence analysis.

	RESULTS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

Ypk1 Has a More Prominent Role in Maintaining Viability Than Ykr2

The two protein kinases encoded by the YPK1 and YKR2/YPK2 genes are very similar to each other and functionally redundant at the genetic level (Chen et al., 1993; Casamayor et al., 1999). Yeast cells missing either Ypk1 or Ykr2 are viable, but cells lacking both proteins are inviable, indicating that these enzymes share an essential function. However, several observations suggest that Ypk1 plays the predominant role in executing this essential function. First, ypk1 mutants are slow growing at 30°C (Maurer, 1988; Chen et al., 1993), whereas ykr2 cells do not display any obvious growth phenotype, compared with otherwise isogenic YPK1⁺ YKR2⁺ control cells (Figure 1). Moreover, we found that the slow-growth phenotype of ypk1 cells is strongly exacerbated at lower temperatures, even at 26°C (Figure 1). In essence, ypk1 mutants are cold sensitive and ykr2 mutants are not.

View larger version (32K): [in this window] [in a new window]   Figure 1.   Phenotypes of ypk1 mutants. ypk1 cells (but not ykr2 cells) grow slowly at 30°C and are cold sensitive. Serial dilutions of exponentially growing wild-type (WT; YPH499) and derived ypk1 (YES3) and ykr2 (YES1) mutants were spotted on YPGlc plates and grown for 3 d at the indicated temperatures (26, 30, and 35°C).

Among the close mammalian relatives of Ypk1 and Ykr2 is p70 S6 kinase (50% identity in the catalytic domain). Activation of mammalian p70 S6 kinase by mitogens is blocked by rapamycin, an immunosuppressive drug (Chung et al., 1992; Kuo et al., 1992; Thomas, 1993). Therefore, we tested whether loss of either Ypk1 or Ykr2 conferred on yeast cells elevated sensitivity to this agent. Compared with wild-type cells, we found that ypk1 cells, but not ykr2 cells, were hypersensitive (~10-fold) to the growth inhibitory effect of rapamycin (Schnieders, 1996; Torrance, 2000), providing a second distinction between ypk1 and ykr2 mutants. We found that ypk1 cells (but not ykr2 cells) were also hypersensitive to hygromycin B, valinomycin, polyoxin D, cycloheximide (Torrance, 2000), and caffeine (Bezman, unpublished observations). These results suggested that ypk1 cells are generally more permeable to drugs and provided indirect evidence for a defect or perturbation in the cell envelope in ypk1 cells (see below). When overexpressed, either YPK1 or YKR2 was able to restore the normal level of drug sensitivity (Roelants, unpublished observations). Given the fact that Pkh1 and Pkh2 are upstream activators of Ypk1 and Ykr2 (Casamayor et al., 1999), it was of interest to test whether loss of either Pkh1 or Pkh2 might also confer a drug-sensitive phenotype. However, neither a pkh1 mutant nor a pkh2 mutant showed any degree of hypersensitivity to the compounds mentioned above, compared with the parental strain (Torrance, 2000).

Catalytically inactive (kinase-dead) alleles of protein kinases frequently act as dominant-negatives (Herskowitz, 1987). Hence, we tested whether overexpression of catalytically inactive versions of Ypk1 and Ykr2 would be toxic to cells. We constructed two such derivatives altered in the invariant Lys found in conserved kinase motif II (Hanks and Hunter, 1995). We showed that Ypk1(K376A) and Ykr2(K373A) are indeed catalytically nonfunctional in vitro and unable to complement the lethality of ypk1 ykr2 cells in vivo (Torrance, 2000). To test whether these alleles behave in a dominant-negative manner when overexpressed from an inducible promoter, plasmids pGAL-YPK1-(K376A-KD) and pGAL-YKR2-(K373A-KD) were introduced into wild-type cells (YPH499) and into ypk1 (YES3) and ykr2 (YES1) mutants, selecting for transformants on SC-Leu medium containing Glc as the carbon source. The resulting transformants then were streaked onto SC-Leu medium containing Gal/Suc to select for maintenance of the plasmid and to induce expression of either kinase-dead Ypk1 or kinase-dead Ykr2. High-level expression of catalytically inactive Ypk1 was growth inhibitory to all three cell types; however, the strongest growth inhibition was observed in ypk1 cells and the mildest was observed in wild-type cells (Figure 2A). In contrast, high-level expression of catalytically inactive Ykr2 had no detectably detrimental effect on growth in any of the strains (Figure 2A). To rule out the possibility that this differential effect was due to a difference in the level of expression of these proteins, Ypk1, Ypk1(K376A), Ykr2, and Ykr2(K373A) were tagged at their C termini with a c-Myc epitope and introduced into ypk1 or ykr2 strains. Identical amounts of protein from extracts of the resulting transformants were immunoprecipitated with anti-Myc mAb 9E10 antibodies, resolved by SDS-PAGE, and visualized by immunoblotting with polyclonal anti-Ypk1 or anti-Ykr2 antibodies. This analysis verified that the proteins were expressed at equivalent levels (Figure 2B). The fact that kinase-dead Ypk1 was able to effectively impede its own function and that of Ypk2, and the fact the converse was not true, provided a third independent indication that Ypk1 plays the more predominant role.

View larger version (49K): [in this window] [in a new window]   Figure 2.   Overexpression of catalytically inactive Ypk1 inhibits growth. (A) Dominant-negative effect of inactive Ypk1. Wild-type cells (WT; YPH499), and ypk1 (YES3) and ykr2 (YES1) mutants were transformed, as indicated, with either an empty vector (YEp352GAL) or the same vector expressing from the GAL1 promoter either full-length Ypk1 (pGAL-YPK1), a catalytically inactive (kinase-dead) ypk1 allele (pGAL-YPK1-KD; pAM48), full-length Ykr2 (pGAL-YKR2; pAM59), or a catalytically inactive (kinase-dead) ykr2 allele (pGAL-YKR2-KD; pAM61). Transformants were selected on glucose-containing medium and then representative isolates were streaked to single colonies on selective medium containing either Glc (left) or Gal (right) as the carbon source and grown for 3 d at 30°C. (B) Equivalent overexpression confirmed by immunoblotting. Cultures of the resulting transformants were grown at 30°C in SCGal/Suc-Leu medium, induced by addition of galactose (2% final concentration) for 3 h. After harvesting the cells by centrifugation, extracts were prepared, and an identical amount of total protein (1 mg) from each extract was subjected to immunoprecipitation with anti-Myc mAb 9E10, as described in MATERIALS AND METHODS. After washing, the immunoprecipitates were solubilized and resolved by electrophoresis on an SDS-slab gel. The species corresponding to Ypk1 and Ypk2 were visualized by immunoblotting with rabbit polyclonal anti-Ypk1 (left) or anti-Ykr2 (right) antibodies, respectively.

Pkh1 Preferentially Activates Ypk1 and Pkh2 Preferentially Activates Ykr2

Purified Pkh1 phosphorylates and activates purified Ypk1 in vitro (Casamayor et al., 1999). To examine the state of activation of Ypk1 and Ykr2 in cell extracts and its dependence on the function of Pkh1 and Pkh2, we developed an immune-complex kinase assay. Cell extracts were prepared from strains expressing c-Myc epitope-tagged derivatives of Ypk1 or Ykr2, immunoprecipitated with anti-Myc mAb 9E10, and samples of the resulting immunoprecipitates were examined for protein content by SDS-PAGE and for catalytic activity using a specific peptide substrate (Cross-tide) and [-³²P]ATP in a filter binding assay (Alessi et al., 1995). As independent negative controls to assess the nonspecific background, extracts were prepared from cells expressing untagged Ypk1 and Ykr2 and from cells expressing kinase-dead derivatives of Ypk1 and Ykr2. Immune complexes from wild-type cells expressing wild-type Ypk1-myc showed ~10-fold increase in phosphotransferase activity compared with both negative controls: immune complexes from wild-type cells expressing untagged Ypk1 (Figure 3A, top) and immune complexes from wild-type cells expressing catalytically inactive Ypk1-myc (Torrance, 2000). When Ypk1-myc was isolated from pkh1 cells, however, the increase in activity was reproducibly 40-60% lower than that observed in wild-type cells, whereas within experimental error, the recovery of Ypk1-myc activity was unaffected in pkh2 cells (Figure 3A, top). Most tellingly, activity was greatly increased (4-fold) when Ypk1-myc was isolated from cells cooverexpressing Pkh1 but only modestly elevated (~1.5-fold) when Pkh2 was cooverexpressed (Figure 3A, top). Because Ypk1-myc and Pkh1 (or Pkh2) were both expressed from multicopy plasmids carrying the GAL1 promoter, which compete for a limiting pool of the Gal4 transactivator, the total amount of Ypk1 produced was reduced (Figure 3A, bottom); thus, the increase in specific activity when Ypk1-myc and Pkh1 were co-overexpressed is even more dramatic than the observed increase in total activity. Moreover, immunoprecipitated Ypk1-myc ran as a set of multiple bands that were collapsed into a single band of faster mobility upon treatment with a phosphatase (Figure 3A, bottom). Phosphatase-treated samples were no longer catalytically active (Torrance, unpublished observations). These findings suggest that activation is due to phosphorylation and that activation of Ypk1 is more dependent on Pkh1 than on Pkh2.

View larger version (22K): [in this window] [in a new window]   Figure 3.   Preferential activation of Ypk1 and Ykr2 by Pkh1 and Pkh2. (A) Pkh1 differentially activates Ypk1. Top, wild-type (WT; W303-1B), pkh1 (AC301), and pkh2 (YPT67) cells overexpressing from the GAL1 promoter on plasmids either Ypk1 (pAM75) or Ypk1-myc (pAM76), in the absence or presence of co-overexpression from the GAL1 promoter on plasmids of either Pkh1 (pAM73) or Pkh2 (pAM79), as indicated, were grown to mid-exponential phase and induced with galactose for 3 h. Extracts were prepared and identical amounts of total protein (1 mg) were immunoprecipitated with anti-Myc mAb 9E10. The immune complexes were washed extensively with protein kinase assay buffer and then incubated with a specific peptide substrate (Cross-tide) and [-32P]ATP, and the resulting product measured, as described in MATERIALS AND METHODS. Bottom, samples of each immunoprecipitate were treated with phosphatase in the absence and presence of phosphatase inhibitors, and examined by SDS-PAGE, as described in MATERIALS AND METHODS. (B) Pkh2 differentially activates Ykr2. Wild-type (WT; W303-1B), pkh1 (AC301), and pkh2 (YPT67) cells overexpressing from the GAL1 promoter on plasmids either Ykr2 (pAM1) or Ykr2-Myc (pAM78), in the absence or presence of co-overexpression from the GAL1 promoter on plasmids of either Pkh1 (pAM73) or Pkh2 (pAM79), as indicated, were grown to mid-exponential phase and induced with galactose for 3 h. Extracts were prepared and activity was measured, as in A. Values shown in A and B represent the average of three independent experiments, each performed in duplicate, and the error bars represent the range of values observed.

Immune complexes from wild-type cells expressing wild-type Ykr2-myc showed approximately a 10-fold increase in phosphotransferase activity compared with both negative controls: immune complexes from wild-type cells expressing untagged Ykr2 (Figure 3B) and immune complexes from wild-type cells expressing catalytically inactive Ykr2-myc (Torrance, 2000). When Ykr2-myc was isolated from either pkh1 or pkh2 cells, however, the increase in activity was reproducibly lower than that observed in wild-type cells, suggesting that both Pkh1 and Pkh2 contribute to phosphorylation and activation of Ykr2. Total activity was stimulated approximately threefold when Ykr2-myc was recovered from cells co-overexpressing Pkh2, but only ~1.5-fold when Pkh1 was co-overexpressed (Figure 2B), indicating that phosphorylation and activation of Ykr2 are more responsive to Pkh2 than to Pkh1.

Loss of PKH2 (but Not PKH1) Exacerbates Slow Growth of ypk1 Cells

The biochemical assays discussed above indicated that Pkh1 preferentially activates Ypk1 and Pkh2 preferentially activates Ykr2. Given that both phk1 pkh2 and ypk1 ykr2 double mutants are inviable (Casamayor et al., 1999), if the discrimination observed in vitro with overexpressed proteins is even more stringent in vivo when these enzymes are expressed at their normal levels then it might be expected that certain mutant combinations might display genetic interaction. To construct all possible double mutant combinations between either ypk1 or ykr2 and either pkh1 or pkh2, a ypk1 haploid was crossed to a pkh1 strain and to a pkh2 strain to create two diploid strains: PKH1/pkh1::TRP1 YPK1/ypk1::HIS3 and PKH2/pkh2::HIS3 YPK1/ypk1::TRP1. Likewise, a ykr2 haploid was crossed to a pkh1 strain and to a pkh2 strain to create two additional diploid strains: PKH1/pkh1::TRP1 YKR2/ykr2::HIS3 and PKH2/pkh2::HIS3 YKR2/ykr2::TRP1. The four doubly heterozygous diploid strains were sporulated. After tetrad dissection, viable Trp⁺ His⁺ haploid spores were readily recovered from all four diploids, indicating that all four double mutants (pkh1 ypk1, pkh2 ypk1, pkh1 ykr2, and pkh2 ykr2) are viable (Figure 4A). However, all of the pkh2 ypk1 spore clones grew significantly more slowly than any of the ypk1 spore clones or any of the pkh2 spore clones, when either streaked to single colonies on plates (Figure 4A) or examined by more definitive spot tests (Figure 4B). This finding provides genetic evidence in support of the biochemical results that the primary and physiologically relevant upstream activator of Ykr2 in vivo is Pkh2 (and not Pkh1). Nonetheless, a yeast cell can survive with either member of these two tiers of protein kinases. Hence, Pkh1 and Pkh2 must each be able to phosphorylate and activate either Ypk1 or Ykr2 to at least some significant degree.

View larger version (69K): [in this window] [in a new window]   Figure 4.   Slow growth of ypk1 cells is exacerbated by absence of Pkh2 (but not Pkh1). (A) Four spores of tetratype asci produced by doubly heterozyous diploids derived from the following four crosses were streaked to single colonies and tested for growth on YPGlc plates at 30°C: top left, a ypk1 strain (YFR107) against a pkh1 strain (YFR105); top right, a ypk1 strain (YFR107) against a pkh2 strain (YFR106); bottom left, a ykr2 strain (YFR119) against a pkh1 (YFR105) strain; and bottom right, a ykr2 strain (YFR64) against a pkh2 (YFR106) strain. (B) Serial dilutions of exponentially growing cultures of the indicated genotypes derived, respectively, from the crosses ypk1 (YFR107) against pkh1 (YFR105), left side, and ypk1 (YFR107) against pkh2 (YFR106), right side, were spotted on YPGlc plates and grown for 2 d at 30°C.

Loss of PKH1 (but Not PKH2) Alleviates Toxicity of Hyperactive Ypk1

Ypk1 and Ykr2 share 88% identity within their 252-residue kinase domains and 75% identity within their downstream 75-residue C-terminal extensions. Ypk1 and Ykr2 also share considerable similarity within their 350-353-residue amino-terminal extensions: 22% identity within the first ~100 residues and strikingly, 65% identity within the next 250 residues. To investigate what the large amino-terminal domain might contribute to the function of Ypk1, a truncation allele of Ypk1 was constructed in which the entire amino terminus (residues 2-336) was deleted. The YPK1(2--336) allele, encoding Ypk1-N, commences with Ser337; in Ypk1, the first Gly of the GxGxxG motif conserved in all protein kinases (Hanks and Hunter, 1995) lies at residue 354. To permit its conditional expression, YPK1(2-336) was inserted in a multicopy vector under control of the GAL1 promoter. Induction of the resulting plasmid, pGAL-YPK1-N (pAM101), in a wild-type strain (W303-1B) on galactose-containing medium was toxic as judged by the exceedingly slow growth of single colonies (Figure 5). Despite its toxicity, overexpression of Ypk1-N was capable of restoring growth (albeit very slowly) to an otherwise inviable ypk1 ykr2 double mutant (Torrance, 2000). The observed toxicity required the catalytic activity of Ypk1-N because a kinase-dead derivative, Ypk1(K376A)-N, was not detectably growth inhibitory (Figure 4), even though immunoblotting indicated that, after induction, Ypk1-N and Ypk1(K376A)-N were expressed at equivalently high levels (Torrance, unpublished observations). Revealingly, the toxicity of Ypk1-N was also alleviated in cells lacking Pkh1, but not in cells lacking Pkh2 (Figure 5). The fact that Pkh1 was required for the dominant toxicity of Ypk1-N provides genetic evidence in support of the biochemical results that the primary and physiologically relevant upstream activator of Ypk1 in vivo is Pkh1 (and not Pkh2).

View larger version (53K): [in this window] [in a new window]   Figure 5.   Absence of Pkh1 (but not Pkh2) alleviates toxicity of constitutively active Ypk1. Wild-type (WT; W303-1B), pkh1 (AC301), or pkh2 (YPT67) strains were transformed with either an empty vector (YEp352GAL) or the same vector expressing from the GAL1 promoter either normal Ypk1 (pAM75), the C-terminal catalytic domain of Ypk1 (Ypk1-N; pAM101), or a catalytically inactive derivative of the C-terminal catalytic domain of Ypk1 (Ypk1-KD-N; pFR30). The resulting transformants were selected on glucose-containing medium and then representative isolates were streaked onto selective medium containing either Glc (left) or Gal (right) as the carbon source. Growth was assessed after 3 d at 30°C.

Differential Subcellular Localization of Pkh1, Pkh2, Ypk1, and Ykr2

One explanation for the observed preferential phosphorylation of Ypk1 by Pkh1, and of Ykr2 by Pkh2, is that the activating enzyme and its downstream target are confined to the same subcellular compartment. As an initial approach to examine localization, each of these four proteins was tagged at its N terminus with three tandem in-frame repeats of GFP and expressed from the GAL1 promoter in a multicopy plasmid. Both 3GFP-Pkh1 and 3GFP-Pkh2 were able to complement the temperature sensitivity of a pkh1^ts pkh2 strain at restrictive temperature (37°C) on galactose-containing medium and even on glucose-containing medium (Roelants, unpublished observations), indicating that each construct was functional. Similarly, 3GFP-Ypk1 and 3GFP-Ykr2 retained their biological function (and transcriptional control was tighter) because each construct was able to complement the temperature sensitivity of ypk1-1ts ykr2 cells at the nonpermissive temperature (37°C) on galactose-containing medium (but not on glucose-containing medium) (Roelants, unpublished observations). In addition, as judged by immunoblotting with anti-GFP antibodies, each of the four tagged proteins was expressed intact and had the molecular weight expected for the full-length chimeric protein (Roelants, unpublished observations).

Live wild-type cells expressing each of the four fusions to 3GFP were examined under the fluorescence microscope (Figure 6). The 3GFP-Ypk1 chimera was found exclusively in the cytosol and was excluded from both the vacuole (whose position was observed by phase contrast microscopy of the same field) and the nucleus (whose position was revealed by growing the cells in the DNA-specific dye DAPI). In contrast, the 3GFP-Ykr2 chimera accumulated in the nucleus, congruent with the DAPI-stained DNA, although it was also readily detectable in the cytoplasm. Interestingly, when fused to 3GFP, the catalytic domain of Ypk1 (Ypk1N), which by itself is toxic when overexpressed (see above), was located predominantly in the nucleus, unlike full-length 3GFP-Ypk1, suggesting that its toxicity may arise largely from its mislocalization. The same patterns of distribution for Ypk1 and Ykr2 were also observed if the cells were fixed, permeabilized, and stained, respectively, with polyclonal anti-Ypk1 and anti-Ykr2 antibodies (Torrance, unpublished observations). Likewise, identical patterns of distribution were observed when cells expressing Ypk1-myc or Ykr2-myc were examined by indirect immunofluorescence using anti-c-Myc mAb 9E10 (Roelants, unpublished observations).

View larger version (93K): [in this window] [in a new window]   Figure 6.   Subcellular localization of GFP-tagged Ypk1, Ykr2, Pkh1, and Pkh2. Wild-type (YPH499) cells were transformed with low copy number (CEN DNA-based) plasmids expressing from the GAL1 promoter either 3GFP-Ypk1 (pFR33), 3GFP-Ypk1-N (pFR34), 3GFP-Ykr2 (pER2), 3GFP-Pkh1 (pFR37), or 3GFP-Pkh2 (pER3), as indicated. The transformants were grown to mid-exponential phase at 30°C in SCRaf/Suc-Leu, induced with galactose (2%) for 3 h, and samples of each culture were viewed directly under a fluorescence microscope. To permit visualization of the position of the nucleus, DAPI was added to the medium (1 µg/ml final concentration) during the last hour of induction.

As observed for 3GFP-Ypk1, 3GFP-Pkh1 was localized exclusively to the cytosol, and clearly excluded from both the vacuole and the nucleus (Figure 6). The most prominent feature of the 3GFP-Pkh1 staining was, however, bright puncta or larger patches situated at the cell cortex. These dots are not congruent with actin patches, as was revealed by costaining with rhodamine-labeled phalloidin (Roelants, unpublished observations). The same distribution pattern was observed if cells expressing Pkh1-(HA)₃ were fixed, permeabilized, and examined by indirect immunofluorescence by using an anti-HA mAb and an appropriate fluorescently tagged secondary antibody (Roelants, unpublished observations). Unlike 3GFP-Pkh1, 3GFP-Pkh2 was not excluded from the nucleus, but like 3GFP-Pkh1, the most prominent feature of the staining was a large number of punctate bodies immediately subtending the plasma membrane (Figure 6), which were also distinct from actin patches (Roelants, unpublished observations).

Thus, taken together, these observations indicate that Pkh2 and Ykr2 are able to enter a compartment (the nucleus) from which Pkh1 and Ypk1 are normally excluded. Thus, these findings help to explain, at least in part, the greater dependence of Ypk1 activation on Pkh1 and the greater dependence of Ykr2 activation on Pkh2.

Genetic Analysis of Ypk1 and Ykr2 Function by Selection of Dosage Suppressors

To identify gene products that may be involved in processes both upstream and downstream of Ypk1 and Ykr2, we selected, first, for genes that when overexpressed from a URA3-marked multicopy vector, were able to restore growth to ypk1-1^ts ykr2 cells at an otherwise nonpermissive temperature (35°C), as described in MATERIALS AND METHODS. From 20,000 Ura⁺ transformants, we recovered 18 plasmids that were able to support growth reproducibly at the restrictive temperature (Table 2). As expected, seven independent isolates of YKR2 and one isolate of YPK1 were obtained. Two of the other suppressor genes obtained, one encoding a putative chaperone (HLJ1) and the other encoding a component of RNA polymerase II holoenzyme (SRB4), may rescue because they stabilize or elevate expression of the temperature-sensitive Ypk1-1 enzyme, although this hypothesis was not tested directly. Another suppressor plasmid carried the YPC1 gene, which encodes an enzyme that can generate phytosphingosine from the corresponding phytoceramide (Mao et al., 2000) and hence presumably rescues by hyperstimulating Pkh1 and Pkh2. Indeed, we have shown previously that elevated Pkh1 can restore growth to ypk1-1^ts ykr2 cells at otherwise restrictive temperature (Casamayor et al., 1999). Indeed, when excised from the original isolate and overexpressed from a completely different vector, YPC1 rescues the temperature sensitivity of ypk1-1^ts ykr2 cells (Roelants, unpublished observations). In contrast, at least one other of the genes from the same insert, RPS6B, was not a suppressor on its own (Roelants, unpublished observations).

View this table: [in this window] [in a new window]   Table 2.  Dosage suppressors of the temperature-sensitive lethality of ypk1-1ts ykr2cells

Revealingly, among the seven remaining dosage suppressors, two plasmids carried a single intact open reading frame corresponding to the EXG1 gene, which encodes the major exo-(1,3)-glucanase involved in cell wall remodeling (Larriba et al., 1995). Indeed, when excised from the original isolate and expressed from a constitutive promoter (ADH1) in a completely different multicopy vector (see MATERIALS AND METHODS), elevated expression of EXG1 reproducibly suppressed, albeit weakly, the temperature-sensitive growth defect of ypk1-1^ts ykr2 cells, even at 37°C (Figure 7A). Also obtained were two isolates of a locus (YBL104c) of unknown function, but which seems from the phenotype of a null allele to also have effects on cell wall structure (Obermaier et al., 1995). Another suppressor plasmid isolated carries multiple open reading frames, one of which is a candidate chitinase (Jacq et al., 1997), which may also influence cell wall structure. At least one of the other genes carried on this same plasmid, FRQ1 (Hendricks et al., 1999), is not responsible for the suppression and does not contribute to the suppression (Roelants, unpublished observations). The final two dosage suppressors encoded proteins that might act by enhancing the efficiency with which enzymes involved in cell wall biosynthesis or remodeling are delivered to their final destination and/or are activated there. One plasmid carried GOT1, which specifies a membrane protein thought to enhance the function of a t-SNARE heavy chain, Sed5, involved in vesicle-mediated protein transport from the endoplasmic reticulum (ER) to the Golgi (Conchon et al., 1999). The other plasmid carried only PLB1, which specifies the phospholipase B that is primarily responsible for the conversion of phosphatidylcholine and phosphatidylethanolamine in the exocellular leaflet of the plasma membrane to lysophosphatidylcholine (and glycerophosphocholine) and lyso-phosphatidylethanolamine (and glycerophosphoethanolamine), respectively (Lee et al., 1994). It is well documented that the activity of many classes of membrane-associated enzymes can be influenced dramatically (either stimulated or inhibited), depending on the nature of the phospholipids (or their derivatives) with which those enzymes associate (Dowhan, 1997).

View larger version (54K): [in this window] [in a new window]   Figure 7.   Relationship between dosage suppressor (EXG1) and extragenic suppressor (kex2). (A) Overexpression of EXG1 suppresses the temperature sensitivity of ypk1-1ts ykr2 cells. A temperature-sensitive ypk1-1ts ykr2 strain (YPT40) was transformed with either an empty vector (pAD4M) or the same vector expressing from the ADH1 promoter either YPK1 (pADH-YPK1) or EXG1 (pAM88). Growth of the resulting transformants was assessed after 2 d at 30° and 37°C, as indicated. (B) Deletion of KEX2 suppresses the temperature sensitivity of ypk1-1ts ykr2 cells. A ypk1-1ts ykr2 strain (YAN2) was crossed to a kex2 strain (KRY24), and the resulting diploid cells (YFR66) were sporulated and dissected. The four spores of a tetratype ascus derived from this diploid were recovered and tested for growth on YPGlc at 30 and 37°C, as indicated. (C) Suppression by kex2 requires EXG1. A MATa ypk1-1ts ykr2 kex2 strain, derived as described in B, was crossed to an exg1 strain (YFR84) and the resulting diploid cells were sporulated and dissected. Serial dilutions of cultures of the indicated genotypes were spotted on YPGlc plates and growth was assessed after 3 d at 30 and 37°C, respectively. (D) Either kex2 cells or rot2 cells lacking Mpk1 are inviable. A kex2 strain (KRY24) was crossed to a mpk1 strain (YFR128), and the resulting diploid cells were sporulated and dissected on plates containing 1.2 M sorbitol. The four spores of a tetratype ascus derived from this diploid were recovered and tested for growth on YPGlc and YPGlc containing 1 M sorbitol at 30°C. The same procedure was applied to diploid cells resulting from crossing a rot2